Finding new ways to avoid intraoperative anemia could go a long way toward improving outcomes for female CABG patients. The full analysis, based on more than 1.4 million patients, was published in the Journal of the American College of Cardiology.

The issue at the center of this recall, which includes both the HeartMate II and HeartMate 3 LVAD, is the gradual buildup of biological materials. This can impact the device's performance, creating a heightened risk of injury or death. 

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

An independent heart team blinded to ICA results was able to deliver helpful guidance for CABG procedures for 99.1% of patients using just CCTA and FFR_CT alone. This approach is safe and feasible, researchers wrote, and the next step is to gather additional data. 

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

Researchers explored data from nearly 70,000 patients, sharing their findings in the American Journal of Cardiology.

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.

"This finding suggests racial and gender bias as a potential contributor to the organ acceptance decision-making process," researchers wrote in JAMA.